25,951 XNAS Volume
XNAS 21 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Michael Houghton | Director | Purchase of securities on an exchange or from another person at price $ 15.61 per share. | 30 Dec 2024 | 3,202 | 3,202 (0%) | 0% | 15.6 | 49,998 | Common Stock |
| Nicole S White | Chief Manufacturing Officer | Sale of securities on an exchange or to another person at price $ 16.30 per share. | 18 Nov 2024 | 40 | 11,871 (0%) | 0% | 16.3 | 652 | Common Stock |
| Jason A. Okazaki | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 14.81 per share. | 03 Oct 2024 | 197 | 14,904 (0%) | 0% | 14.8 | 2,918 | Common Stock |
| Nicole S White | Chief Manufacturing Officer | Sale of securities on an exchange or to another person at price $ 14.81 per share. | 03 Oct 2024 | 157 | 11,911 (0%) | 0% | 14.8 | 2,325 | Common Stock |
| Jason A. Okazaki | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 14.23 per share. | 02 Aug 2024 | 981 | 15,101 (0%) | 0% | 14.2 | 13,962 | Common Stock |
| Nicole S White | Chief Manufacturing Officer | Sale of securities on an exchange or to another person at price $ 14.23 per share. | 02 Aug 2024 | 785 | 12,068 (0%) | 0% | 14.2 | 11,173 | Common Stock |
| Anthony E. Altig | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 2,750 | 2,750 | - | - | Stock Option (right to buy) | |
| Michael Houghton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 2,750 | 2,750 | - | - | Stock Option (right to buy) | |
| William R. Ringo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 2,750 | 2,750 | - | - | Stock Option (right to buy) | |
| Susan Mahony | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 2,750 | 2,750 | - | - | Stock Option (right to buy) | |
| Gina Consylman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 2,750 | 2,750 | - | - | Stock Option (right to buy) | |
| John G. McHutchison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 2,750 | 2,750 | - | - | Stock Option (right to buy) | |
| Lisa R. Johnson-Pratt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 2,750 | 2,750 | - | - | Stock Option (right to buy) | |
| Jason A. Okazaki | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 14.93 per share. | 23 May 2024 | 549 | 16,082 (0%) | 0% | 14.9 | 8,199 | Common Stock |
| John G. McHutchison | Director | Sale of securities on an exchange or to another person at price $ 14.93 per share. | 23 May 2024 | 2,117 | 19,104 (0%) | 0% | 14.9 | 31,615 | Common Stock |
| Jeanette M. Bjorkquist | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 14.92 per share. | 23 May 2024 | 24 | 3,142 (0%) | 0% | 14.9 | 358 | Common Stock |
| Nicole S White | Chief Manufacturing Officer | Sale of securities on an exchange or to another person at price $ 14.94 per share. | 23 May 2024 | 172 | 12,853 (0%) | 0% | 14.9 | 2,569 | Common Stock |
| Jason A. Okazaki | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Apr 2024 | 4,166 | 17,992 (0%) | 0% | 0 | Common Stock | |
| Jason A. Okazaki | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 12.71 per share. | 29 Apr 2024 | 1,569 | 16,423 (0%) | 0% | 12.7 | 19,937 | Common Stock |
| William E. Delaney | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Apr 2024 | 3,333 | 16,109 (0%) | 0% | 0 | Common Stock | |
| Nicole S White | Chief Manufacturing Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Apr 2024 | 3,333 | 14,280 (0%) | 0% | 0 | Common Stock | |
| Nicole S White | Chief Manufacturing Officer | Sale of securities on an exchange or to another person at price $ 12.71 per share. | 29 Apr 2024 | 1,255 | 13,025 (0%) | 0% | 12.7 | 15,947 | Common Stock |
| John G. McHutchison | Director | Sale of securities on an exchange or to another person at price $ 13.07 per share. | 01 Apr 2024 | 1,206 | 21,221 (0%) | 0% | 13.1 | 15,765 | Common Stock |
| Jason A. Okazaki | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 13.07 per share. | 29 Mar 2024 | 354 | 13,826 (0%) | 0% | 13.1 | 4,627 | Common Stock |
| Jason A. Okazaki | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2024 | 65,000 | 65,000 | - | - | Stock Option (right to buy) | |
| Jeanette M. Bjorkquist | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2024 | 850 | 3,280 (0%) | 0% | 0 | Common Stock | |
| Jeanette M. Bjorkquist | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 13.07 per share. | 29 Mar 2024 | 114 | 3,166 (0%) | 0% | 13.1 | 1,490 | Common Stock |
| Jeanette M. Bjorkquist | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2024 | 1,550 | 1,550 | - | - | Stock Option (right to buy) | |
| William E. Delaney | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2024 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Nicole S White | Chief Manufacturing Officer | Sale of securities on an exchange or to another person at price $ 13.07 per share. | 29 Mar 2024 | 197 | 10,947 (0%) | 0% | 13.1 | 2,575 | Common Stock |
| Nicole S White | Chief Manufacturing Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2024 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Jason A. Okazaki | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 12.87 per share. | 27 Mar 2024 | 392 | 14,180 (0%) | 0% | 12.9 | 5,045 | Common Stock |
| Jason A. Okazaki | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 1.09 per share. | 02 Aug 2023 | 11,827 | 164,786 (0%) | 0% | 1.1 | 12,867 | Common Stock |
| William E. Delaney | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 1.09 per share. | 02 Aug 2023 | 9,461 | 142,744 (0%) | 0% | 1.1 | 10,293 | Common Stock |
| Jeanette M. Bjorkquist | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 1.07 per share. | 24 Jul 2023 | 844 | 26,688 (0%) | 0% | 1.1 | 900 | Common Stock |
| Jason A. Okazaki | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 50,000 | 176,613 (0%) | 0% | 0 | Common Stock | |
| William E. Delaney | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 40,000 | 152,205 (0%) | 0% | 0 | Common Stock | |
| William E. Delaney | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 0.96 per share. | 30 May 2023 | 4,232 | 112,205 (0%) | 0% | 1.0 | 4,046 | Common Stock |
| Anthony E. Altig | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| William R. Ringo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Susan Mahony | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Gina Consylman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| John G. McHutchison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Lisa R. Johnson-Pratt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Michael Houghton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Jason A. Okazaki | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2023 | 35,000 | 133,174 (0%) | 0% | 0 | Common Stock | |
| Jason A. Okazaki | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 1.04 per share. | 22 May 2023 | 6,561 | 126,613 (0%) | 0% | 1.0 | 6,825 | Common Stock |
| John G. McHutchison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2023 | 117,500 | 295,132 (0%) | 0% | 0 | Common Stock | |
| John G. McHutchison | Director | Sale of securities on an exchange or to another person at price $ 1.04 per share. | 22 May 2023 | 25,972 | 169,160 (0%) | 0% | 1.0 | 27,019 | Common Stock |
| William E. Delaney | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2023 | 35,000 | 122,998 (0%) | 0% | 0 | Common Stock | |
| William E. Delaney | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 1.04 per share. | 22 May 2023 | 6,561 | 116,437 (0%) | 0% | 1.0 | 6,825 | Common Stock |
| Jeanette M. Bjorkquist | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2023 | 1,500 | 27,806 (0%) | 0% | 0 | Common Stock | |
| Jeanette M. Bjorkquist | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 1.04 per share. | 22 May 2023 | 274 | 27,532 (0%) | 0% | 1.0 | 285 | Common Stock |
| John G. McHutchison | Director | Sale of securities on an exchange or to another person at price $ 0.82 per share. | 30 Mar 2023 | 14,883 | 177,632 (0%) | 0% | 0.8 | 12,252 | Common Stock |
| Jason A. Okazaki | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2023 | 470,000 | 470,000 | - | - | Stock Option (right to buy) | |
| Jason A. Okazaki | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 0.82 per share. | 29 Mar 2023 | 4,247 | 98,174 (0%) | 0% | 0.8 | 3,496 | Common Stock |
| William E. Delaney | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2023 | 140,000 | 140,000 | - | - | Stock Option (right to buy) | |
| William E. Delaney | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 0.82 per share. | 29 Mar 2023 | 3,421 | 85,498 (0%) | 0% | 0.8 | 2,816 | Common Stock |
| Jason A. Okazaki | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 1.02 per share. | 27 Mar 2023 | 4,693 | 102,421 (0%) | 0% | 1.0 | 4,785 | Common Stock |
| Jason A. Okazaki | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 12,500 | 107,114 (0%) | 0% | 0 | Common Stock | |
| William E. Delaney | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 10,000 | 88,919 (0%) | 0% | 0 | Common Stock | |
| Jeanette M. Bjorkquist | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 0.82 per share. | 16 Feb 2023 | 774 | 23,806 (0%) | 0% | 0.8 | 637 | Common Stock |
| Jeanette M. Bjorkquist | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 6,250 | 24,580 (0%) | 0% | 0 | Common Stock | |
| Jeanette M. Bjorkquist | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 2,000 | 2,000 | - | - | Stock Option (right to buy) | |
| Jeanette M. Bjorkquist | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | |
| John G. McHutchison | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 2.13 per share. | 08 Aug 2022 | 12,314 | 192,515 (0%) | 0% | 2.1 | 26,200 | Common Stock |
| Jason A. Okazaki | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 250,000 | 250,000 | - | - | Stock Option (right to buy) | |
| William E. Delaney | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 200,000 | 200,000 | - | - | Stock Option (right to buy) | |
| Michael P. Samar | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.22 per share. | 25 Jul 2022 | 2,020 | 77,228 (0%) | 0% | 2.2 | 4,479 | Common Stock |
| William E. Delaney | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 1.92 per share. | 31 May 2022 | 4,164 | 76,419 (0%) | 0% | 1.9 | 8,005 | Common Stock |
| Anthony E. Altig | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Richard D. DiMarchi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| William R. Ringo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Susan Mahony | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Gina Consylman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Lisa R. Johnson-Pratt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Michael Houghton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Jason A. Okazaki | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2022 | 125,000 | 125,000 | - | - | Stock Option (right to buy) | |
| Jason A. Okazaki | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2022 | 31,250 | 95,883 (0%) | 0% | 0 | Common Stock | |
| Jason A. Okazaki | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 2.17 per share. | 29 Mar 2022 | 1,269 | 94,614 (0%) | 0% | 2.2 | 2,750 | Common Stock |
| Jason A. Okazaki | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2022 | 31,250 | 31,250 | - | - | Performance-based Restricted Stock Units | |
| John G. McHutchison | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2022 | 83,750 | 83,750 | - | - | Performance-based Restricted Stock Units | |
| John G. McHutchison | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2022 | 83,750 | 209,443 (0%) | 0% | 0 | Common Stock | |
| John G. McHutchison | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 2.17 per share. | 29 Mar 2022 | 4,614 | 204,829 (0%) | 0% | 2.2 | 10,000 | Common Stock |
| John G. McHutchison | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2022 | 335,000 | 335,000 | - | - | Stock Option (right to buy) | |
| Michael P. Samar | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2022 | 26,250 | 79,033 (0%) | 0% | 0 | Common Stock | |
| Michael P. Samar | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2022 | 26,250 | 26,250 | - | - | Performance-based Restricted Stock Units | |
| Michael P. Samar | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2022 | 105,000 | 105,000 | - | - | Stock Option (right to buy) | |
| Michael P. Samar | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.17 per share. | 29 Mar 2022 | 2,285 | 76,748 (0%) | 0% | 2.2 | 4,953 | Common Stock |
| Luisa M. Stamm | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2022 | 22,500 | 22,500 | - | - | Performance-based Restricted Stock Units | |
| Luisa M. Stamm | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2022 | 22,500 | 41,353 (0%) | 0% | 0 | Common Stock | |
| Luisa M. Stamm | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 2.17 per share. | 29 Mar 2022 | 1,038 | 40,315 (0%) | 0% | 2.2 | 2,250 | Common Stock |
| Luisa M. Stamm | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2022 | 90,000 | 90,000 | - | - | Stock Option (right to buy) | |
| William E. Delaney | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2022 | 25,000 | 79,121 (0%) | 0% | 0 | Common Stock | |
| William E. Delaney | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2022 | 25,000 | 25,000 | - | - | Performance-based Restricted Stock Units | |
| William E. Delaney | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2022 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| William E. Delaney | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 2.17 per share. | 29 Mar 2022 | 1,038 | 78,083 (0%) | 0% | 2.2 | 2,250 | Common Stock |
| Jason A. Okazaki | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 2.24 per share. | 28 Mar 2022 | 4,617 | 64,633 (0%) | 0% | 2.2 | 10,363 | Common Stock |
| John G. McHutchison | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 3.60 per share. | 09 Aug 2021 | 12,156 | 125,693 (0%) | 0% | 3.6 | 43,781 | Common Stock |
| Michael P. Samar | SVP, Fin. & Bus. Ops, PFO, PAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2021 | 10,938 | 51,783 (0%) | 0% | 0 | Common Stock | |
| Michael Houghton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jul 2021 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| William E. Delaney | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 4.03 per share. | 27 May 2021 | 4,129 | 53,121 (0%) | 0% | 4.0 | 16,637 | Common Stock |
| Anthony E. Altig | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2021 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Richard D. DiMarchi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2021 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| William R. Ringo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2021 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Myron Z. Holubiak | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2021 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Susan Mahony | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2021 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Gina Consylman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2021 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Lisa Johnson-Pratt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2021 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Jason A. Okazaki | Chief Legal & Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2021 | 82,500 | 82,500 | - | - | Stock Option (right to buy) | |
| Jason A. Okazaki | Chief Legal & Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2021 | 13,750 | 67,250 (0%) | 0% | 0 | Common Stock | |
| John G. McHutchison | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2021 | 305,000 | 305,000 | - | - | Stock Option (right to buy) | |
| Luisa M. Stamm | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2021 | 67,500 | 67,500 | - | - | Stock Option (right to buy) | |
| Luisa M. Stamm | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2021 | 11,250 | 18,853 (0%) | 0% | 0 | Common Stock | |
| William E. Delaney | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2021 | 11,250 | 56,250 (0%) | 0% | 0 | Common Stock | |
| William E. Delaney | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2021 | 67,500 | 67,500 | - | - | Stock Option (right to buy) | |
| Jacqueline S. Papkoff | SVP-CSO Microbiome | Sale of securities on an exchange or to another person at price $ 6.15 per share. | 14 Dec 2020 | 1,297 | 37,364 (0%) | 0% | 6.2 | 7,983 | Common Stock |
| Luisa M. Stamm | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 5.10 per share. | 09 Nov 2020 | 4,397 | 7,603 (0%) | 0% | 5.1 | 22,404 | Common Stock |
| Gina Consylman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Oct 2020 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| John G. McHutchison | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 21.76 per share. | 07 Aug 2020 | 11,395 | 138,605 (0%) | 0% | 21.8 | 247,907 | Common Stock |
| John G. McHutchison | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 22.50 per share. | 07 Aug 2020 | 756 | 137,849 (0%) | 0% | 22.5 | 17,010 | Common Stock |
| Anthony E. Altig | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2020 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Richard D. DiMarchi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2020 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Alan James Lewis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2020 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Helen S. Kim | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2020 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Myron Z. Holubiak | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2020 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Susan Mahony | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2020 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| William E Delaney | CSO, Virology | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2020 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| William E Delaney | CSO, Virology | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2020 | 45,000 | 45,000 (0%) | 0% | 0 | Common Stock | |
| Richard James Colonno | EVP & CSO, Virology Ops | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2020 | 34,000 | 34,000 | - | - | Stock Option (right to buy) | |
| Richard James Colonno | EVP & CSO, Virology Ops | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2020 | 17,000 | 144,821 (0%) | 0% | 0 | Common Stock | |
| Richard James Colonno | EVP & CSO, Virology Ops | Sale of securities on an exchange or to another person at price $ 15.04 per share. | 27 Mar 2020 | 7,812 | 137,009 (0%) | 0% | 15.0 | 117,524 | Common Stock |
| Jacqueline S. Papkoff | SVP-CSO Microbiome | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2020 | 34,000 | 34,000 | - | - | Common Stock (right to buy) | |
| Jacqueline S. Papkoff | SVP-CSO Microbiome | Sale of securities on an exchange or to another person at price $ 14.22 per share. | 27 Mar 2020 | 1,254 | 38,661 (0%) | 0% | 14.2 | 17,831 | Common Stock |
| Jacqueline S. Papkoff | SVP-CSO Microbiome | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2020 | 17,000 | 39,915 (0%) | 0% | 0 | Common Stock | |
| John G. McHutchison | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2020 | 50,000 | 150,000 (0%) | 0% | 0 | Common Stock | |
| John G. McHutchison | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2020 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Jason A. Okazaki | Chief Legal & Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2020 | 50,000 | 52,500 (0%) | 0% | 0 | Common Stock | |
| Jason A. Okazaki | Chief Legal & Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2020 | 250,000 | 250,000 | - | - | Stock Option (right to buy) | |
| William R. Ringo | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 28 Feb 2020 | 2,000 | 17,465 (0%) | 0% | 0 | Common Stock | |
| William R. Ringo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2020 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Derek A. Small | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2020 | 125,000 | 828,791 (2%) | 0% | 0 | Common Stock | |
| Jacqueline S. Papkoff | SVP-CSO Microbiome | Sale of securities on an exchange or to another person at price $ 21.00 per share. | 13 Dec 2019 | 1,460 | 22,915 (0%) | 0% | 21.0 | 30,662 | Common Stock |
| Richard James Colonno | EVP & CSO, Virology Ops | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2019 | 33,061 | 166,939 | - | - | Stock Option (right to buy) | |
| Richard James Colonno | EVP & CSO, Virology Ops | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 12 Dec 2019 | 33,061 | 127,821 (0%) | 0% | 25.0 | 826,578 | Common Stock |
| Richard James Colonno | EVP & CSO, Virology Ops | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.03 per share. | 12 Dec 2019 | 33,061 | 160,882 (0%) | 0% | 7.0 | 232,419 | Common Stock |
| Luisa M. Stamm | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Nov 2019 | 12,000 | 12,000 (0%) | 0% | 0 | Common Stock | |
| Luisa M. Stamm | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Nov 2019 | 165,000 | 165,000 | - | - | Stock Option (right to buy) | |
| Jacqueline S. Papkoff | SVP-CSO Microbiome | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2019 | 27,500 | 27,500 | - | - | Stock Options (right to buy) | |
| Michael P. Samar | SVP, Finance and Bus. Ops, PAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2019 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Michael P. Samar | SVP, Finance and Bus. Ops, PAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2019 | 2,500 | 20,327 (0%) | 0% | 0 | Common Stock | |
| John G. McHutchison | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Sep 2019 | 25,000 | 25,000 | - | - | Performance-based Restricted Stock Units | |
| John G. McHutchison | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2019 | 500,000 | 500,000 | - | - | Stock Option (right to buy) | |
| John G. McHutchison | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2019 | 100,000 | 100,000 (0%) | 0% | 0 | Common Stock | |
| Anthony E. Altig | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2019 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Mark Auerbach | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2019 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Richard D. DiMarchi | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2019 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| William R. Ringo | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2019 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Alan James Lewis | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2019 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Helen S. Kim | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2019 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Myron Z. Holubiak | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2019 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Susan Mahony | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2019 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Graham K. Cooper | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2019 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Graham K. Cooper | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2019 | 17,500 | 117,500 (0%) | 0% | 0 | Common Stock | |
| Derek A. Small | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2019 | 65,000 | 65,000 | - | - | Stock Option (right to buy) | |
| Derek A. Small | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2019 | 32,500 | 701,791 (2%) | 0% | 0 | Common Stock | |
| Uri A. Lopatin | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2019 | 27,500 | 27,500 | - | - | Stock Option (right to buy) | |
| Uri A. Lopatin | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2019 | 13,750 | 627,361 (2%) | 0% | 0 | Common Stock | |
| Richard James Colonno | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2019 | 32,500 | 32,500 | - | - | Stock Option (right to buy) | |
| Richard James Colonno | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2019 | 16,250 | 126,250 (0%) | 0% | 0 | Common Stock | |
| Jacqueline S. Papkoff | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2019 | 27,500 | 27,500 | - | - | Stock Option (right to buy) | |
| Jacqueline S. Papkoff | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2019 | 13,750 | 24,375 (0%) | 0% | 0 | Common Stock | |
| Graham K. Cooper | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2018 | 100,000 | 100,000 (0%) | 0% | 0 | Common Stock | |
| Richard James Colonno | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2018 | 20,000 | 110,000 (0%) | 0% | 0 | Common Stock | |
| Jacqueline S. Papkoff | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2018 | 21,250 | 21,250 | - | - | Stock Option (right to buy) | |
| Jacqueline S. Papkoff | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2018 | 10,625 | 10,625 (0%) | 0% | 0 | Common Stock | |
| Richard James Colonno | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2018 | 25,000 | 90,000 (0%) | 0% | 0 | Common Stock | |
| Uri A. Lopatin | Chief Med. Off., VP Res. Dev. | Sale of securities on an exchange or to another person at price $ 40.01 per share. | 05 Sep 2018 | 336 | 613,611 (2%) | 0% | 40.0 | 13,442 | Common Stock |
| Uri A. Lopatin | Chief Med. Off., VP Res. Dev. | Sale of securities on an exchange or to another person at price $ 40.09 per share. | 05 Sep 2018 | 15,204 | 613,947 (2%) | 0% | 40.1 | 609,547 | Common Stock |
| Richard James Colonno | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2018 | 25,000 | 65,000 (0%) | 0% | 0 | Common Stock | |
| Derek A. Small | Director, CEO and President | Purchase of securities on an exchange or from another person at price $ 41.77 per share. | 19 Jul 2018 | 1,200 | 669,291 (2%) | 0% | 41.8 | 50,123 | Common Stock |
| Derek A. Small | Director, CEO and President | Purchase of securities on an exchange or from another person at price $ 41.19 per share. | 19 Jul 2018 | 1,200 | 668,091 (2%) | 0% | 41.2 | 49,428 | Common Stock |
| William R. Ringo | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jul 2018 | 1,000 | 49,000 | - | - | Stock Option (right to buy) | |
| William R. Ringo | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 02 Jul 2018 | 1,000 | 20,465 (0%) | 0% | 7.2 | 7,200 | Common Stock |
| William R. Ringo | None | Sale of securities on an exchange or to another person at price $ 38.50 per share. | 02 Jul 2018 | 1,000 | 19,465 (0%) | 0% | 38.5 | 38,503 | Common Stock |
| Anthony E. Altig | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2018 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Mark Auerbach | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2018 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Richard D. DiMarchi | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2018 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| William R. Ringo | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 30 May 2018 | 1,000 | 20,465 (0%) | 0% | 7.2 | 7,200 | Common Stock |
| William R. Ringo | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2018 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| William R. Ringo | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 May 2018 | 1,000 | 50,000 | - | - | Stock Option (right to buy) | |
| William R. Ringo | None | Sale of securities on an exchange or to another person at price $ 42.47 per share. | 30 May 2018 | 1,000 | 19,465 (0%) | 0% | 42.5 | 42,470 | Common Stock |
| Alan James Lewis | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2018 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Helen S. Kim | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2018 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Myron Z. Holubiak | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2018 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Susan Mahony | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2018 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| William R. Ringo | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2018 | 1,000 | 51,000 | - | - | Stock Option (right to buy) | |
| William R. Ringo | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 01 May 2018 | 1,000 | 20,465 (0%) | 0% | 7.2 | 7,200 | Common Stock |
| William R. Ringo | None | Sale of securities on an exchange or to another person at price $ 43.06 per share. | 01 May 2018 | 1,000 | 19,465 (0%) | 0% | 43.1 | 43,060 | Common Stock |
| William R. Ringo | None | Sale of securities on an exchange or to another person at price $ 49.32 per share. | 02 Apr 2018 | 1,000 | 19,465 (0%) | 0% | 49.3 | 49,320 | Common Stock |
| William R. Ringo | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Apr 2018 | 1,000 | 52,000 | - | - | Stock Option (right to buy) | |
| William R. Ringo | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 02 Apr 2018 | 1,000 | 20,465 (0%) | 0% | 7.2 | 7,200 | Common Stock |
| Jacqueline S. Papkoff | See remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2018 | 106,200 | 106,200 | - | - | Stock Option (right to buy) | |
| Derek A. Small | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2018 | 65,000 | 65,000 | - | - | Stock Option (right to buy) | |
| Derek A. Small | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2018 | 32,500 | 666,891 (3%) | 0% | 0 | Common Stock | |
| Uri A. Lopatin | Chief Med. Off., VP Res. Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2018 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Uri A. Lopatin | Chief Med. Off., VP Res. Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2018 | 7,500 | 629,151 (3%) | 0% | 0 | Common Stock | |
| Richard James Colonno | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2018 | 15,000 | 40,000 (0%) | 0% | 0 | Common Stock | |
| Richard James Colonno | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2018 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Thomas E. Rollins | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2018 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Thomas E. Rollins | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2018 | 3,750 | 3,750 (0%) | 0% | 0 | Common Stock | |
| Graham K. Cooper | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2018 | 220,000 | 220,000 | - | - | Stock Option (right to buy) | |
| Helen S. Kim | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2018 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| William R. Ringo | None | Sale of securities on an exchange or to another person at price $ 56.37 per share. | 01 Mar 2018 | 1,000 | 19,465 (0%) | 0% | 56.4 | 56,370 | Common Stock |
| William R. Ringo | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2018 | 1,000 | 53,000 | - | - | Stock Option (right to buy) | |
| William R. Ringo | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 01 Mar 2018 | 1,000 | 20,465 (0%) | 0% | 7.2 | 7,200 | Common Stock |
| William R. Ringo | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 01 Feb 2018 | 1,000 | 20,465 (0%) | 0% | 7.2 | 7,200 | Common Stock |
| William R. Ringo | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2018 | 1,000 | 54,000 | - | - | Stock Option (right to buy) | |
| William R. Ringo | None | Sale of securities on an exchange or to another person at price $ 46.86 per share. | 01 Feb 2018 | 1,000 | 19,465 (0%) | 0% | 46.9 | 46,860 | Common Stock |
| William R. Ringo | None | Sale of securities on an exchange or to another person at price $ 45.04 per share. | 02 Jan 2018 | 1,000 | 19,465 (0%) | 0% | 45.0 | 45,040 | Common Stock |
| William R. Ringo | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2018 | 1,000 | 55,000 | - | - | Stock Option (right to buy) | |
| William R. Ringo | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 02 Jan 2018 | 1,000 | 20,465 (0%) | 0% | 7.2 | 7,200 | Common Stock |
| Richard James Colonno | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2018 | 25,000 | 25,000 (0%) | 0% | 0 | Common Stock | |
| Susan Mahony | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2017 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| William R. Ringo | None | Sale of securities on an exchange or to another person at price $ 49.37 per share. | 01 Dec 2017 | 1,000 | 19,465 (0%) | 0% | 49.4 | 49,370 | Common Stock |
| William R. Ringo | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2017 | 1,000 | 56,000 | - | - | Stock Option (right to buy) | |
| William R. Ringo | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 01 Dec 2017 | 1,000 | 20,465 (0%) | 0% | 7.2 | 7,200 | Common Stock |
| William R. Ringo | None | Sale of securities on an exchange or to another person at price $ 29.55 per share. | 01 Nov 2017 | 1,000 | 19,465 (0%) | 0% | 29.6 | 29,550 | Common Stock |
| William R. Ringo | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2017 | 1,000 | 57,000 | - | - | Stock Option (right to buy) | |
| William R. Ringo | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 01 Nov 2017 | 1,000 | 20,465 (0%) | 0% | 7.2 | 7,200 | Common Stock |
| William R. Ringo | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jun 2017 | 1,000 | 58,000 | - | - | Stock Option (right to buy) | |
| William R. Ringo | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 23 Jun 2017 | 1,000 | 20,465 (0%) | 0% | 7.2 | 7,200 | Common Stock |
| William R. Ringo | None | Gift of securities by or to the insider at price $ 0.00 per share. | 23 Jun 2017 | 1,000 | 19,465 (0%) | 0% | 0 | Common Stock | |
| William R. Ringo | None | Sale of securities on an exchange or to another person at price $ 33.70 per share. | 23 Jun 2017 | 1,000 | 19,465 (0%) | 0% | 33.7 | 33,700 | Common Stock |
| Anthony E. Altig | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2017 | 7,500 | 7,500 | - | - | Stock Option (Right to Buy) | |
| Mark Auerbach | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2017 | 7,500 | 7,500 | - | - | Stock Option (Right to Buy) | |
| Richard D. DiMarchi | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2017 | 7,500 | 7,500 | - | - | Stock Option (Right to Buy) | |
| William R. Ringo | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2017 | 7,500 | 7,500 | - | - | Stock Option (Right to Buy) | |
| Alan James Lewis | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2017 | 7,500 | 7,500 | - | - | Stock Option (Right to Buy) | |
| Myron Z. Holubiak | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2017 | 7,500 | 7,500 | - | - | Stock Option (Right to Buy) | |
| William R. Ringo | None | Sale of securities on an exchange or to another person at price $ 22.00 per share. | 12 May 2017 | 3,461 | 0 (0%) | 0% | 22 | 76,142 | Common Stock |
| William R. Ringo | None | Gift of securities by or to the insider at price $ 0.00 per share. | 10 May 2017 | 3,461 | 3,461 (0%) | 0% | 0 | Common Stock | |
| William R. Ringo | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 10 May 2017 | 5,000 | 25,465 (0%) | 0% | 7.2 | 36,000 | Common Stock |
| William R. Ringo | None | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.39 per share. | 10 May 2017 | 1,539 | 23,926 (0%) | 0% | 23.4 | 35,997 | Common Stock |
| William R. Ringo | None | Gift of securities by or to the insider at price $ 0.00 per share. | 10 May 2017 | 3,461 | 20,465 (0%) | 0% | 0 | Common Stock | |
| William R. Ringo | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 May 2017 | 5,000 | 59,000 | - | - | Stock Option (Right to Buy) | |
| David J. Barrett | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2017 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Derek A. Small | Director, CEO, President and Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2017 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Uri A. Lopatin | Chief Med. Off., VP Res. Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2017 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | |
| Richard James Colonno | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2017 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Thomas E. Rollins | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2017 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Myron Z. Holubiak | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2016 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Alan James Lewis | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2016 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| William R. Ringo | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2016 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Mark Auerbach | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2016 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Anthony E. Altig | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2016 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Richard D. DiMarchi | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2016 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy | |
| Thomas E. Rollins | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2016 | 40,263 | 40,263 | - | - | Stock Option (Right to Buy) | |
| Thomas E. Rollins | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2016 | 8,245 | 8,245 | - | - | Stock Option (Right to Buy) | |
| Derek Small | Director, CEO and President | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 10 Feb 2016 | 1,555 | 634,391 | - | - | Common Stock, $0.001 par value per share | |
| Derek Small | Director, CEO and President | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 10 Feb 2016 | 8,445 | 632,836 | - | - | Common Stock, $0.001 par value per share | |
| Richard James Colonno | Chief Science Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2016 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| Alan J. Lewis | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2015 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Myron Z. Holubiak | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2015 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| William R. Ringo | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2015 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Mark Auerbach | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2015 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Anthony E. Altig | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2015 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Richard D. DiMarchi | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2015 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| David J. Barrett | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2014 | 741,800 | 741,800 | - | - | Stock Options (right to buy) | |
| David J. Barrett | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2014 | 741,800 | 741,800 | - | - | Stock Options (right to buy) | |
| David J. Barrett | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2014 | 10,000 | 19,396 | - | - | Common Stock | |
| Myron Z. Holubiak | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2014 | 64,000 | 64,000 | - | - | Stock Options (right to buy) | |
| Myron Z. Holubiak | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2014 | 64,000 | 64,000 | - | - | Stock Options (right to buy) | |
| William R. Ringo | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2014 | 64,000 | 64,000 | - | - | Stock Option (right to buy) | |
| William R. Ringo | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2014 | 64,000 | 64,000 | - | - | Stock Option (right to buy) | |
| Mark Auerbach | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2014 | 64,000 | 64,000 | - | - | Stock Options (right to buy) | |
| Anthony E. Altig | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2014 | 64,000 | 64,000 | - | - | Stock Options (Right to Buy) | |
| Anthony E. Altig | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2014 | 64,000 | 64,000 | - | - | Stock Options (Right to Buy) | |
| Richard D. DiMarchi | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2014 | 64,000 | 64,000 | - | - | Stock Option (right to buy) | |
| Richard D. DiMarchi | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2014 | 64,000 | 64,000 | - | - | Stock Option (right to buy) | |
| Russell H. Ellison | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2014 | 800,000 | 800,000 | - | - | Stock Options (right to buy) | |
| Russell H. Ellison | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2014 | 533,333 | 533,333 | - | - | Stock Options (right to buy) | |
| Russell H. Ellison | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2014 | 10,000 | 21,600 | - | - | Common Stock | |
| Uri A. Lopatin | Chief Med. Off., VP Res. Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2014 | 160,000 | 160,000 | - | - | Stock Option (right to buy) | |
| Uri A. Lopatin | Chief Med. Off., VP Res. Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2014 | 160,000 | 160,000 | - | - | Stock Option (right to buy) | |
| Russell H. Ellison | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 27 May 2014 | 13,000 | 58,000 | - | - | Common Stock | |
| David J. Barrett | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 22 May 2014 | 5,980 | 45,980 | - | - | Common Stock | |
| David J. Barrett | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 22 May 2014 | 1,000 | 46,980 | - | - | Common Stock | |
| Russell H. Ellison | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 22 May 2014 | 5,000 | 30,000 | - | - | Common Stock | |
| Russell H. Ellison | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 22 May 2014 | 15,000 | 45,000 | - | - | Common Stock | |
| Anthony E. Altig | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2014 | 25,000 | 40,000 | - | - | Common Stock | |
| Russell H. Ellison | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 21 May 2014 | 10,000 | 25,000 | - | - | Common Stock | |
| David J. Barrett | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 20 May 2014 | 40,000 | 40,000 | - | - | Common Stock | |
| David J. Barrett | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2014 | 213,000 | 213,000 | - | - | Stock Options (right to buy) | |
| Russell H. Ellison | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2014 | 395,500 | 395,500 | - | - | Stock Options (right to buy) | |
| Russell H. Ellison | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2014 | 395,500 | 395,500 | - | - | Stock Options (right to buy) | |
| Russell H. Ellison | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2014 | 200,000 | 150,000 | - | - | Restricted Stock Units | |
| Russell H. Ellison | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2014 | 50,000 | 50,000 | - | - | Phantom Stock | |
| David J. Barrett | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2013 | 200,000 | 150,000 | - | - | Restricted Stock Units | |
| David J. Barrett | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2013 | 50,000 | 50,000 | - | - | Phantom Stock | |
| Russell H. Ellison | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2013 | 50,000 | 50,000 | - | - | Phantom Stock | |
| Russell H. Ellison | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2013 | 200,000 | 150,000 | - | - | Restricted Stock Units | |
| Myron Z. Holubiak | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2013 | 10,000 | 10,000 | - | - | Stock Options (right to buy) | |
| Mark Auerbach | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2013 | 10,000 | 10,000 | - | - | Stock Options (right to buy) | |
| Joseph Felder | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2013 | 10,000 | 10,000 | - | - | Stock Options (right to buy) | |
| Russell H. Ellison | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 04 Feb 2013 | 5,624 | 15,000 | - | - | Common Stock | |
| Russell H. Ellison | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 04 Feb 2013 | 9,376 | 9,376 | - | - | Common Stock | |
| Anthony E. Altig | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2012 | 15,000 | 15,000 | - | - | Common Stock | |
| Anthony E. Altig | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2012 | 35,000 | 35,000 | - | - | Stock Options (Right to Buy) | |
| David J. Barrett | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2012 | 40,000 | 40,000 | - | - | Stock Options (right to buy) | |
| Russell H. Ellison | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2012 | 60,000 | 60,000 | - | - | Stock Options (right to buy) | |
| Thomas Rowland | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2012 | 30,000 | 30,000 | - | - | Stock Options (Right to Buy) | |
| Myron Z. Holubiak | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Nov 2011 | 10,000 | 10,000 | - | - | Stock Options (right to buy) | |
| Mark Auerbach | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Nov 2011 | 10,000 | 10,000 | - | - | Stock Options (right to buy) | |
| Mark Auerbach | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Nov 2011 | 10,000 | 10,000 | - | - | Stock Options (right to buy) | |
| Joseph Felder | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Nov 2011 | 10,000 | 10,000 | - | - | Stock Options (right to buy) | |
| Joseph Felder | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Nov 2011 | 10,000 | 10,000 | - | - | Stock Options (right to buy) | |
| Thomas Rowland | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2011 | 250,000 | 250,000 | - | - | Stock Options (Right to Buy) | |
| David J. Barrett | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2010 | 305,920 | 305,920 | - | - | Stock Options (right to buy) | |
| Russell H. Ellison | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2010 | 573,599 | 573,599 | - | - | Stock Options (right to buy) |